Compare HIW & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIW | RCUS |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.6B |
| IPO Year | 1995 | 2018 |
| Metric | HIW | RCUS |
|---|---|---|
| Price | $32.43 | $27.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $27.57 | ★ $31.90 |
| AVG Volume (30 Days) | ★ 1.6M | 985.3K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 8.43% | N/A |
| EPS Growth | ★ 54.26 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $806,112,000.00 | $247,000,000.00 |
| Revenue This Year | $6.03 | N/A |
| Revenue Next Year | $3.58 | $45.62 |
| P/E Ratio | $113.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.45 | $8.88 |
| 52 Week High | $35.44 | $31.74 |
| Indicator | HIW | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 51.56 |
| Support Level | $32.37 | $25.94 |
| Resistance Level | $33.88 | $28.72 |
| Average True Range (ATR) | 0.77 | 1.45 |
| MACD | -0.23 | -0.11 |
| Stochastic Oscillator | 10.41 | 49.26 |
Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.